Lunit, Labcorp Partner on AI-Powered Digital Pathology Research
The collaboration combines Labcorp's clinical expertise with Lunit's AI algorithms to analyze tumor microenvironments and enhance biomarker discovery.
The collaboration combines Labcorp's clinical expertise with Lunit's AI algorithms to analyze tumor microenvironments and enhance biomarker discovery.
A simulation model shows that annual liquid biopsy screening would increase early-stage cancer detection by up to 30% while cutting stage IV diagnoses by 45%.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
The test measures microRNA-371a-3P biomarker and can guide treatment decisions while reducing need for some CT scans during surveillance.
Sample-to-answer assay delivers results in approximately 45 minutes from nasopharyngeal and nasal swab specimens.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
The multiplex immunoassay measures autoantibodies to the 14-3-3eta protein and aims to reduce diagnostic delays that currently average seven to 10 years.
The quantitative measurement test is designed to aid in myocardial infarction diagnosis using human plasma samples.
The validation enables its use as a blood-based biomarker for inclusion and exclusion in clinical trials in both the United States and Europe.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.